We have established various high-throughput functional assays and are collaborating with the Division of Pre-Clinical Innovation at NIH/NCATS to identify novel mutation-specific ER stress modulators.
We hope to develop highly-targeted clinical trials based on these discovered chemical compounds and novel biotherapeutic proteins to treat ER disease.